Payment overview · 2025
General Payments
$599.12
13 reported records · 2 companies
Healthcare provider profile · identity verified
Greg A Brown, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN CLEMENTE, CA · NPI 1720135346
Verified facts
What the public records show
CMS Open Payments records show Greg A Brown, M.D. received $599.12 in general payments during 2025 across 13 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 51.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $308.56 | 51.5% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $290.56 | 48.5% | 5 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $599.12 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $308.56 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $290.56 | 5 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 441 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 113 |
| Losartan Potassium | Losartan Potassium | 364 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 318 | 95 |
| Metformin Hcl | Metformin Hcl | 316 | 98 |
| Gabapentin | Gabapentin | 219 | 58 |
| Lisinopril | Lisinopril | 193 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 44 |
| Ozempic | Semaglutide | 142 | 29 |
| Furosemide | Furosemide | 139 | 43 |
| Tramadol Hcl | Tramadol Hcl | 130 | 35 |
| Trazodone Hcl | Trazodone Hcl | 127 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 33 |
| Eliquis | Apixaban | 119 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 118 | 32 |
| Memantine Hcl | Memantine Hcl | 118 | 28 |
| Simvastatin | Simvastatin | 118 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 32 |
| Azithromycin | Azithromycin | 112 | 79 |
| Potassium Chloride | Potassium Chloride | 106 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 33 |
| Montelukast Sodium | Montelukast Sodium | 94 | 25 |
| Omeprazole | Omeprazole | 94 | 32 |
| Atenolol | Atenolol | 88 | 27 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 85 | 24 |
| Meloxicam | Meloxicam | 83 | 29 |
| Famotidine | Famotidine | 82 | 25 |
| Benazepril Hcl | Benazepril Hcl | 79 | 22 |
| Allopurinol | Allopurinol | 74 | 21 |
| Jardiance | Empagliflozin | 73 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 23 |
| Mounjaro | Tirzepatide | 70 | 11 |
| Xarelto | Rivaroxaban | 69 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 48 |
| Finasteride | Finasteride | 66 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 20 |
| Promethazine Hcl | Promethazine Hcl | 60 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 19 |
| Alprazolam | Alprazolam | 55 | 14 |
| Eszopiclone | Eszopiclone | 55 | suppressed |
| Carvedilol | Carvedilol | 54 | 13 |
| Donepezil Hcl | Donepezil Hcl | 54 | 14 |
| Mirtazapine | Mirtazapine | 53 | 18 |
| Synthroid | Levothyroxine Sodium | 52 | 15 |
| Spironolactone | Spironolactone | 49 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 14 |
| Methylprednisolone | Methylprednisolone | 48 | 43 |
| Ibuprofen | Ibuprofen | 43 | 13 |
| Digoxin | Digoxin | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 42 | 13 |
| Ezetimibe | Ezetimibe | 41 | 11 |
| Ketoconazole | Ketoconazole | 41 | 24 |
| Lovastatin | Lovastatin | 41 | 11 |
| Testosterone | Testosterone | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 13 |
| Celecoxib | Celecoxib | 40 | 17 |
| Myrbetriq | Mirabegron | 40 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 13 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | 17 |
| Acyclovir | Acyclovir | 37 | 12 |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 21 |
| Temazepam | Temazepam | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 30 |
| Valacyclovir | Valacyclovir Hcl | 35 | 18 |
| Methocarbamol | Methocarbamol | 34 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 15 |
| Prednisone | Prednisone | 34 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | 12 |
| Hydrocortisone | Hydrocortisone | 30 | 16 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | 12 |
| Baclofen | Baclofen | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 21 |
| Dexamethasone | Dexamethasone | 25 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 22 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Estradiol | Estradiol | 22 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Pregabalin | Pregabalin | 22 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Colchicine | Colchicine | 21 | 11 |
| Metronidazole | Metronidazole | 21 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 19 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Trulicity | Dulaglutide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Nystatin | Nystatin | 14 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Tretinoin | Tretinoin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $599.12 · 13 records | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE, Ozempic | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error